Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
McNamara B, Bellone S, Demirkiran C, Hartwich T, Santin A. Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy. Gynecologic Oncology Reports 2023, 48: 101219. PMID: 37325293, PMCID: PMC10265462, DOI: 10.1016/j.gore.2023.101219.Peer-Reviewed Original ResearchUterine serous carcinomaHER2/neuSerous carcinomaT-DXdTreatment optionsRecurrent uterine serous carcinomaDose-limiting side effectEffective treatment optionNew treatment optionsBone painRecurrent diseaseDurable responsesTrastuzumab deruxtecanCA 125Disease burdenSide effectsCarcinomaAntibody drugsTreatmentSignificant reductionDiseaseNeuExperimental treatmentsMetastaticPain